Long-term Follow-up of a Phase 1/2a Clinical Trial of a Stem Cell-Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy.

Saved in:
Bibliographic Details
Title: Long-term Follow-up of a Phase 1/2a Clinical Trial of a Stem Cell-Derived Bioengineered Retinal Pigment Epithelium Implant for Geographic Atrophy.
Authors: Humayun MS; USC Roski Eye Institute, USC Ginsburg Institute for Biomedical Therapeutics and Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Biomedical Engineering, University of Southern California, Los Angeles, California. Electronic address: humayun@usc.edu., Clegg DO; Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California., Dayan MS; USC Roski Eye Institute, USC Ginsburg Institute for Biomedical Therapeutics and Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California., Kashani AH; Wilmer Eye Institute, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland., Rahhal FM; Retina-Vitreous Associates Medical Group, Beverly Hills, California., Avery RL; California Retina Consultants, Santa Barbara, California., Salehi-Had H; Retina Associates of Southern California, Huntington Beach, California., Chen S; Orange County Retina Medical Group, Santa Ana, California., Chan C; Southern California Desert Retina Consultants, Palm Desert, California., Palejwala N; Retinal Consultants of Arizona, Retinal Research Institute LLC, Phoenix, Arizona., Ingram A; Regenerative Patch Technologies, Menlo Park, California., Mitra D; USC Roski Eye Institute, USC Ginsburg Institute for Biomedical Therapeutics and Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California., Pennington BO; Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California; Regenerative Patch Technologies, Menlo Park, California., Hinman C; Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California; Regenerative Patch Technologies, Menlo Park, California., Faynus MA; Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California; Regenerative Patch Technologies, Menlo Park, California., Bailey JK; Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, University of California, Santa Barbara, Santa Barbara, California; Regenerative Patch Technologies, Menlo Park, California., Johnson LV; Regenerative Patch Technologies, Menlo Park, California., Lebkowski JS; Regenerative Patch Technologies, Menlo Park, California.
Source: Ophthalmology [Ophthalmology] 2024 Jun; Vol. 131 (6), pp. 682-691. Date of Electronic Publication: 2023 Dec 30.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1549-4713
DOI:10.1016/j.ophtha.2023.12.028